REVOLUTION - Randomized phasE 2 study of Valproic acid in combination with bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients with ras-mutated metastaTIc cOlorectal caNcer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516844-25-01

Enrollment

200

Registered

2024-12-09

Start date

2019-01-03

Completion date

Unknown

Last updated

2025-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with ras-mutated metastatIc colorectal cancer

Brief summary

PFS progression-free survival

Detailed description

centrally reviewed PFS (CR-PFS)

Interventions

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

DRUGACIDO VALPROICO E SODIO VALPROATO ratiopharm 500 mg compresse a rilascio prolungato

DRUGOxaliplatino Accord 5 mg/ml concentrato per soluzione per infusione

DRUGFLUOROURACILE PFIZER 50 mg/mL

DRUGsolution à diluer pour perfusion

DRUGCapecitabina Glenmark 150 mg comprimidos recubiertos con película EFG

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
PFS progression-free survival	—

Secondary

Measure	Time frame
centrally reviewed PFS (CR-PFS)	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026